Advertisement


Luis G. Paz-Ares, MD, PhD, on IMforte Trial in Extensive-Stage SCLC

2025 ASCO Annual Meeting

Advertisement

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, presents primary results from the phase III IMforte trial, which evaluated lurbinectedin plus atezolizumab as first-line maintenance treatment in patients with extensive-stage small cell lung cancer (SCLC) (Abstract 8006).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
I presented at ASCO this year the results of the IMforte trial. This is a randomized phase 3 study of the combination of lurbinectedin plus atezolizumab versus atezolizumab alone as first-line maintenance treatment for patients with extensive-stage small cell lung cancer. There is a clear need to improve the efficacy of those regimens in the first-line setting. Currently, chemoimmunotherapy provides responses to most patients, but relapses typically happen very early on, and long-term survival is a rare event. Our group has shown the synergistic effect in immunocompetent models of lurbinectedin plus atezolizumab, and we have previously conducted phase 1 and phase 2 trials. We showed that this combination is feasible in the clinic at full doses with a predictable safety profile and encouraging activity. Therefore, we developed this phase 3 trial where patients with extensive-stage small cell lung cancer, previously untreated and without brain metastases, were treated with four courses of induction treatment with carboplatin, etoposide, and atezolizumab. Only those patients who had a response or disease stabilization and still had a good performance status were randomized in the maintenance phase, which is the randomized portion of the study. Patients were randomized in a 1:1 fashion to receive either the standard of care maintenance with atezolizumab or the experimental arm with lurbinectedin plus atezolizumab. The primary endpoints were progression-free survival (PFS) by an independent review facility and overall survival (OS). A total of 483 patients were included. Patient characteristics were typical of those seen in similar phase 3 studies and were balanced. The PFS primary endpoint by an independent review facility was clearly superior for patients treated with the combination, with a hazard ratio of 0.54, which was statistically significant with a p-value of 0.0001. That translated into an increase in median PFS from 2.1 to 5.4 months in patients treated with the combination. When PFS was assessed by investigators, the results were consistent, and we appreciated the benefit across all relevant subgroup analyses included in the trial. The second primary endpoint, OS, showed similar results and improvement that was statistically significant with a hazard ratio of 0.73 in favor of the combination, with a p-value of 0.0174. That translated into an increase in median OS from 10.6 to 13.2 months. In terms of response, the data were consistent, and we appreciated an increase in the number of side effects with the combination as expected, but the toxicity profile was predictable, manageable, and very few patients required discontinuation—6% compared to 3% with atezolizumab alone. Hematological toxicity was more common, but we did not observe bleeding events, febrile neutropenia, and the infection rate was similar in the two arms. Altogether, we can conclude that this trial shows a statistically significant and clinically relevant improvement in PFS and OS for patients treated with lurbinectedin plus atezolizumab compared to atezolizumab alone. The safety profile was predictable, with an increase in some side effects that were typically low grade, low discontinuation rate, and all events were resolved. We believe that lurbinectedin plus atezolizumab may become a new standard of care for patients in first-line maintenance for extensive-stage small cell lung cancer.

Related Videos

Breast Cancer
Issues in Oncology

Neil M. Iyengar, MD, on Cancer Risk Reduction: Effects of Menopausal HRT and GLP-1 RAs

Neil M. Iyengar, MD, of Memorial Sloan Kettering Cancer Center, reviews several studies that aimed to answer two questions: does menopausal hormone therapy (HRT) impact overall survival and breast cancer–specific mortality in younger women diagnosed with high-risk disease (Abstract 10506); and do GLP-1 receptor agonists (GLP-1 RAs), a class of weight-loss medications, have cancer risk reduction properties (Abstracts 10507 and 10508). 

Leukemia

Nitin Jain, MD, on Front-Line Therapies for CLL: Research Highlights From ASCO 2025

Nitin Jain, MD, Professor in the Department of Leukemia and Director of the Leukemia CAR-T Program at The University of Texas MD Anderson Cancer Center, shares his expert point of view on data presented on front-line therapies for chronic lymphocytic leukemia (CLL) presented at the 2025 ASCO Annual Meeting. 

Genomics/Genetics

Arelis Esther Martir-Negron, MD, on Prevalence of BRCA Variants in Hispanic Residents of South Florida

South Florida has a unique demographic, characterized by a large Hispanic population with ancestries from the Caribbean and Central and South America. Arelis Esther Martir-Negron, MD, of Miami Cancer Institute, presents data from a retrospective analysis that sought to determine the frequency and spectrum of BRCA pathogenic/likely pathogenic variants in this population (Abstract 10579). 

Lung Cancer

Jamie E. Chaft, MD, FASCO, on Resectable EGFR-Mutated NSCLC: NeoADAURA Results

Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, reviews results of the NeoADAURA trial, which looked at neoadjuvant osimertinib with or without chemotherapy vs chemotherapy alone in patients with resectable EGFR-mutated non–small cell lung cancer (NSCLC) (Abstract 8001). 

Issues in Oncology

Suneel Deepak Kamath, MD, on Disparities in NIH and Federal Funding Across Different Cancer Types

Suneel Deepak Kamath, MD, of the Cleveland Clinic, reports findings from a study that evaluated funding from the NIH and Congressionally Directed Medical Research Programs supporting lung, breast, colorectal, pancreatic, hepatobiliary, ovarian, cervical, endometrial, and prostate cancers, as well as leukemia, lymphoma, and melanoma, from 2013 to 2022 (Abstract 11025). 

Advertisement

Advertisement




Advertisement